Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets

MT Newswires Live

Feb 02

Orthocell (ASX:OCC) said it plans to focus on completing launch planning for its fiscal 2027 entry into the UK and European Union markets, according to a Monday Australian bourse filing.

Its total revenue for the first half of fiscal 2026 came in at AU$6.2 million, up from AU$4.2 million in the year-ago period.

Orthocell estimated that it requires around 10,000 unit sales of its Remplir nerve repair product per annum in the US to reach cash breakeven, which is less than 1% of the addressable market, per the filing.

The firm's shares rose 1% in early trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608887369"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608887369\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608887369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 07:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608887369","market":"sh","top_or_hot":-1,"title":"Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets","media":"MT Newswires Live","content":"<html><body><p> Orthocell (ASX:OCC) said it plans to focus on completing launch planning for its fiscal 2027 entry into the UK and European Union markets, according to a Monday Australian bourse filing.</p><p>Its total revenue for the first half of fiscal 2026 came in at AU$6.2 million, up from AU$4.2 million in the year-ago period.</p><p>Orthocell estimated that it requires around 10,000 unit sales of its Remplir nerve repair product per annum in the US to reach cash breakeven, which is less than 1% of the addressable market, per the filing.</p><p>The firm's shares rose 1% in early trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-02 07:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Orthocell (ASX:OCC) said it plans to focus on completing launch planning for its fiscal 2027 entry into the UK and European Union markets, according to a Monday Australian bourse filing.</p><p>Its total revenue for the first half of fiscal 2026 came in at AU$6.2 million, up from AU$4.2 million in the year-ago period.</p><p>Orthocell estimated that it requires around 10,000 unit sales of its Remplir nerve repair product per annum in the US to reach cash breakeven, which is less than 1% of the addressable market, per the filing.</p><p>The firm's shares rose 1% in early trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCC.AU","symbol_name":"ORTHOCELL LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608887369","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608887369","pubTimestamp":1769989904,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell  said it plans to focus on completing launch planning for its fiscal 2027 entry into the UK and European Union markets, according to a Monday Australian bourse filing.Its total revenue for the first half of fiscal 2026 came in at AU$6.2 million, up from AU$4.2 million in the year-ago period.Orthocell estimated that it requires around 10,000 unit sales of its Remplir nerve repair product per annum in the US to reach cash breakeven, which is less than 1% of the addressable market, per the filing.The firm's shares rose 1% in early trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCC.AU":"ORTHOCELL LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Orthocell计划于2027财年进入英国和欧盟市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1},"content_text":"Orthocell (ASX:OCC) said it plans to focus on completing launch planning for its fiscal 2027 entry into the UK and European Union markets, according to a Monday Australian bourse filing.Its total revenue for the first half of fiscal 2026 came in at AU$6.2 million, up from AU$4.2 million in the year-ago period.Orthocell estimated that it requires around 10,000 unit sales of its Remplir nerve repair product per annum in the US to reach cash breakeven, which is less than 1% of the addressable market, per the filing.The firm's shares rose 1% in early trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}